About: Dicentrine is a research topic. Over the lifetime, 78 publications have been published within this topic receiving 1190 citations. The topic is also known as: (S)-(+)-dicentrine.
TL;DR: The requirement of a suboptimal conformation to achieve DNA binding appears to make dicentrine a weaker topoisomerase II inhibitor than the very planar oxoaporphine alkaloid liriodenine, suggesting that it may be possible to modulate DNA binding and biologic activity of drugs by modifications affecting their ability to adopt planar conformations.
TL;DR: Two new aporphine alkaloids, isofiliformine and cassythic acid, along with 22 known compounds were isolated from whole herb of Cassytha filiformis, and had potent vasorelaxing effects on precontracted rat aortic preparations.
Abstract: Two new aporphine alkaloids, isofiliformine (1) and cassythic acid (3), along with 22 known compounds were isolated from whole herb of Cassytha filiformis. Cassythic acid (3), cassythine (4), neolitsine (7), and dicentrine (8) had potent vasorelaxing effects on precontracted rat aortic preparations with mean IC50 values between 0.08 and 2.48 µM. Compounds 1, 1,2-methylenedioxy-3,10,11-trimethoxyaporphine (2), (−)-O-methylflavinatine (10), (−)-salutaridine (11), isohamnetin-3-O-β-glucoside, and isohamnetin-3-O-rutinoside exerted moderate vessel-relaxing activities with IC50 values from 16.50 to 32.81 µM at the test concentrations.
TL;DR: In this article, the effect of several agents possessing vasodilating activities on rat mesangial cell growth and collagen synthesis was investigated using cell counting and a modified MTT assay, and it was shown that dipyridamole, pentoxifylline, dicentrine, prazosin and doxazosin all caused a dose-dependent inhibition of serum-stimulated rat cell proliferation.
Abstract: Mesangial cell activation and extracellular matrix accumulation are hallmarks of many forms of glomerulonephropathy. We investigated the effect of several agents possessing vasodilating activities on rat mesangial cell growth and collagen synthesis. Using cell counting and a modified MTT assay, it was shown that dipyridamole, pentoxifylline, dicentrine, prazosin and doxazosin all caused a dose-dependent inhibition of serum-stimulated rat mesangial cell proliferation. Platelet-derived growth factor-induced cell proliferation was also inhibited by doxazosin and pentoxifylline. Dipyridamole and pentoxifylline inhibited collagen synthesis in confluent mesangial cells while dicentrine and doxazosin did not. The procollagen alpha 1 (I) mRNA expression was also decreased by dipyridamole and pentoxifylline. These results suggested that, in addition to dipyridamole, pentoxifylline and alpha 1-adrenoceptor blockers may have a potential to delay the progression of chronic glomerulopathy associated with mesangial proliferation.
TL;DR: Four alkaloids, dicentrine, glaucine, protopine, and alpha-allocryptopine were identified as the compounds responsible for the antifungal activity of this plant.
TL;DR: Data indicated that d-dicentrine has potential anti-tumor applications and significantly inhibited the tumor incidence of leukemia cell line K562 in SCID mice.
Abstract: d-Dicentrine, a naturally occurring aporphine type isoquinoline alkaloid, isolated from the root of Lindera megaphylla Hemsl. (Lauraceae), was evaluated for its potential anti-cancer activity. We found d-dicentrine significantly inhibited the growth of human hepatoma cell line HuH-7 by delaying its doubling time in tissue culture. An in vitro colony forming assay showed that d-dicentrine decreased the colony formation efficiency in both hepatoma cell lines, HuH-7 and MS-G2, used in our study. Biosyntheses of the macromolecules DNA and RNA were also strongly inhibited. An MTT assay in 21 tumor cell lines also revealed that d-dicentrine was most cytotoxic to esophageal carcinoma HCE-6, lymphoma cell lines Molt-4 and CESS, leukemia cell lines HL60 and K562, and hepatoma cell line MS-G2. An in vitro tumor growing assay in the Severe Combined immunodeficiency (SCID) mice showed that intraperitoneal injection of d-dicentrine at the dose of 100 micrograms twice a week for 4 weeks significantly inhibited the tumor incidence of leukemia cell line K562 in SCID mice. All these data indicated that d-dicentrine has potential anti-tumor applications.